These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21346736)

  • 1. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers.
    Marquand AF; De Simoni S; O'Daly OG; Williams SC; Mourão-Miranda J; Mehta MA
    Neuropsychopharmacology; 2011 May; 36(6):1237-47. PubMed ID: 21346736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: a multi-class pattern recognition approach.
    Marquand AF; O'Daly OG; De Simoni S; Alsop DC; Maguire RP; Williams SC; Zelaya FO; Mehta MA
    Neuroimage; 2012 Apr; 60(2):1015-24. PubMed ID: 22266414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory.
    Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
    Psychol Med; 2014 Feb; 44(3):633-46. PubMed ID: 23597077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
    J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.
    Kratz O; Studer P; Baack J; Malcherek S; Erbe K; Moll GH; Heinrich H
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):81-9. PubMed ID: 22227291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
    Rubia K; Halari R; Cubillo A; Mohammad AM; Brammer M; Taylor E
    Neuropharmacology; 2009 Dec; 57(7-8):640-52. PubMed ID: 19715709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
    Fumagalli F; Cattaneo A; Caffino L; Ibba M; Racagni G; Carboni E; Gennarelli M; Riva MA
    Pharmacol Res; 2010 Dec; 62(6):523-9. PubMed ID: 20691787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys.
    Cubillo A; Smith AB; Barrett N; Giampietro V; Brammer MJ; Simmons A; Rubia K
    Cereb Cortex; 2014 Jan; 24(1):174-85. PubMed ID: 23048018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential long-term medication impact on executive function and delay aversion in ADHD.
    Rubio Morell B; Hernández Expósito S
    Appl Neuropsychol Child; 2019; 8(2):140-157. PubMed ID: 29244542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate does not improve interference control during a working memory task in young patients with attention-deficit hyperactivity disorder.
    Prehn-Kristensen A; Krauel K; Hinrichs H; Fischer J; Malecki U; Schuetze H; Wolff S; Jansen O; Duezel E; Baving L
    Brain Res; 2011 May; 1388():56-68. PubMed ID: 21385569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
    Fu Z; Yuan J; Pei X; Zhang K; Xu C; Hu N; Xie R; Zhao Y; Wang Y; Yang L; Cao Q
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):709-719. PubMed ID: 35524732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
    Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate enhances brain activation and deactivation responses to visual attention and working memory tasks in healthy controls.
    Tomasi D; Volkow ND; Wang GJ; Wang R; Telang F; Caparelli EC; Wong C; Jayne M; Fowler JS
    Neuroimage; 2011 Feb; 54(4):3101-10. PubMed ID: 21029780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased default-mode variability is related to reduced task-performance and is evident in adults with ADHD.
    Mowinckel AM; Alnæs D; Pedersen ML; Ziegler S; Fredriksen M; Kaufmann T; Sonuga-Barke E; Endestad T; Westlye LT; Biele G
    Neuroimage Clin; 2017; 16():369-382. PubMed ID: 28861338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
    Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
    Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.